Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Case report

Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer

Authors: Jean-David Fumet, Mark Wickre, Jean-Philippe Jacquot, Marie-Helene Bizollon, Adrien Melis, André Vanoli, Erika Viel

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Metastatic breast cancer (MBC) rest an incurably disease associated with bad prognosis and a median overall survival of 23–31 months. There are several treatment options including chemotherapy and sometimes endocrine therapy. Currently, there is no standard treatment for patients with MBC who have already benefited from anthracyclines and taxanes therapy. Many drugs like capecitabine, eribulin, gemcitabine, vinorelbin and liposomal doxorubicin are conventionally used as monotherapy. One important complication from MBC is life threating visceral crisis that needs a fast-effective treatment.

Case presentation

We report here a case of an evolution of metastatic breast cancer with lymphangitic carcinomatosis after taxane based chemotherapy and endocrine therapy. This 37-year-old woman was referred to our hospital with complaints of dyspnea and dry cough. There was clinical concern for visceral crisis and a chemotherapy with eribulin was initiated. Pulmonary lymphangitic carcinomatosis disappeared and the patient achieved a good partial response.

Conclusion

We reported a case of rapid, positive treatment response using eribulin on metastatic breast cancer with visceral crisis and we could quoted others. Therefore, eribulin may be an appropriate chemotherapeutic option in instances requiring rapid symptom control.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
2.
Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer. J Clin Oncol. 2008;26(30):4891–8.CrossRefPubMedPubMedCentral
3.
Harb WA. Management of patients with hormone receptor–positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res. 2015;7:37–46.CrossRefPubMedPubMedCentral
4.
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, et al. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2016.
5.
Bonotto M, Gerratana L, Iacono D, Minisini AM, Rihawi K, Fasola G, et al. Treatment of metastatic breast Cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines? The Oncologist. 2015;20(7):719–24.CrossRefPubMedPubMedCentral
6.
Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, et al. Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions. Cancer Res. 2011;71(2):496–505.CrossRefPubMed
7.
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. The Lancet. 2011;377(9769):914–23.CrossRef
8.
Lorusso V, Cinieri S, Latorre A, Porcu L, Del Mastro L, Puglisi F, et al. Efficacy and safety of eribulin in taxane-refractory patients in the ‘real world’. Future Oncol. 2017;13(11):971–8.CrossRefPubMed
9.
Hominal S, Falchero L, Perol M, Guérin JC. Carcinomatous lymphangitis. Presse Medicale Paris Fr 1983. 1999;28(18):979–84.
10.
Albiges L, Chamming’s F, Duclos B, Stern M, Motzer RJ, Ravaud A, et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2012;23(8):1943–53.CrossRef
11.
Khachekian A, Shargh S, Arabian S. Pulmonary Lymphangitic Carcinomatosis From Metastatic Gastric Adenocarcinoma: Case Report. J Am Osteopath Assoc. 2015;115(5):332–7.CrossRefPubMed
12.
Bruce DM, Heys SD, Eremin O. Lymphangitis carcinomatosa: a literature review. J R Coll Surg Edinb. 1996;41(1):7–13.PubMed
13.
Kikuchi N, Shiozawa T, Ishii Y, Satoh H, Noguchi M, Ohtsuka M. A patient with pulmonary lymphangitic carcinomatosis successfully treated with TS-1 and cisplatin. Intern Med Tokyo Jpn. 2007;46(8):491–4.CrossRef
14.
Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, et al. A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2012;7(3):574–8.CrossRefPubMedPubMedCentral
Metadata
Title
Successfully treatment by eribulin in visceral crisis: a case of lymphangitic carcinomatosis from metastatic breast cancer
Authors
Jean-David Fumet
Mark Wickre
Jean-Philippe Jacquot
Marie-Helene Bizollon
Adrien Melis
André Vanoli
Erika Viel
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4725-7

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Resveratrol induces autophagy-dependent apoptosis in HL-60 cells

Research article

Race is an independent predictor of survival in patients with soft tissue sarcoma of the extremities

Case report

FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report

Research article

Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening

Research article

Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients

Research article

Screening for distress in patients with primary brain tumor using distress thermometer: a systematic review and meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits